Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism by Spires-Jones, Tara et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Environmental enrichment rescues protein deficits in a mouse
model of Huntington's disease, indicating a possible disease
mechanism
Citation for published version:
Spires-Jones, T, Grote, HE, Varshney, NK, Cordery, PM, van Dellen, A, Blakemore, C & Hannan, AJ 2004,
'Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a
possible disease mechanism' Journal of Neuroscience, vol. 24, no. 9, pp. 2270-6. DOI:
10.1523/JNEUROSCI.1658-03.2004
Digital Object Identifier (DOI):
10.1523/JNEUROSCI.1658-03.2004
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of Neuroscience
Publisher Rights Statement:
''After 6 months the work becomes available to the public to copy, distribute, or display under a Creative
Commons Attribution-Noncommercial-Share Alike 3.0 Unported license.''
http://www.jneurosci.org/site/misc/ifa_policies.xhtml
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
Development/Plasticity/Repair
Environmental Enrichment Rescues Protein Deficits in a
Mouse Model of Huntington’s Disease, Indicating a Possible
Disease Mechanism
Tara L. Spires, Helen E. Grote, Neelash K. Varshney, Patricia M. Cordery, Anton van Dellen, Colin Blakemore, and
Anthony J. Hannan
University Laboratory of Physiology, University of Oxford, Oxford OX1 3PT, United Kingdom
Huntington’s disease (HD) is a devastating neurodegenerative disorder caused by a CAG repeat expansion encoding an extended poly-
glutamine tract in the huntingtin protein. Transgenic mice expressing a human huntingtin transgene containing an expanded CAG repeat
(R6/1 model) develop a neurodegenerative disorder closely resembling human HD. Previous work demonstrated that environmental
enrichment delays the onset of motor symptoms in this mouse model. We confirmed that at 5 months of age, enrichment ameliorates
motor symptoms (assessed using the rotarod test) and prevents loss of body weight induced by the HD transgene. We further examined
molecular consequences of enrichment by determining changes in protein levels in the neostriatum, hippocampus, and anterior cortex
using quantitative Western blot analysis. Non-enriched HD mice have severe reductions in BDNF in the hippocampus and striatum at 5
months, which are entirely rescued by enrichment. BDNF levels are unaltered by HD in the anterior cortex, suggesting that enrichment
might prevent HD-induced impairment of anterograde transport of this neurotrophin to the striatum. NGF is unaffected by HD. Non-
enriched HD mice also exhibit deficits in dopamine and cAMP-regulated phosphoprotein (32 kDa) in striatum and anterior cortex.
Environmental enrichment rescues the cortical but not the striatal deficit at 5 months. These results suggest that environmental enrich-
ment benefits animals at early stages of the disease by rescuing protein deficits, possibly through rescuing transcription or protein
transport problems.
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Introduction
Huntington’s disease (HD) is a fatal neurodegenerative disorder
characterized by progressive cognitive, psychological, and motor
symptoms. It is a trinucleotide repeat disease (Harper, 1996)
caused by an expanded CAG repeat in exon 1 of the huntingtin
gene, which translates into an abnormally long polyglutamine
tract in the huntingtin protein (Huntington’s Disease Collabora-
tive Research Group, 1993). Neuropathology of HD includes
neuronal death in the corpus striatum and neocortex, preceded
by neuronal dysfunction (for review, see Davies and Ramsden,
2001). The mechanisms leading from the expanded polyglu-
tamine tract to cell dysfunction and death are not yet fully
understood.
Several transgenic mouse models have been developed to
study HD, of which the R6 lines are probably the best character-
ized. These mice express exon 1 of the huntingtin gene containing
an expanded CAG repeat. The R6/1 model used in these experi-
ments, with some 112–120 repeats, closely resembles human HD
in symptomatology and neuropathology (Mangiarini et al., 1996;
Sathasivam et al., 1999).
Environmental enrichment has been shown to delay disease
progress in the R6/1 mouse model of HD (van Dellen et al.,
2000a) and in the related R6/2 model with a longer expansion
(Hockly et al., 2002). Interestingly, remotivation therapy im-
proves functioning in HD patients (Sullivan et al., 2001), indicat-
ing that environmental stimulation may also benefit human HD
sufferers. However, the mechanisms underlying the beneficial
effects of enrichment remain unknown.
HD is known to cause transcriptional dysregulation of several
molecular systems, including neurotransmitter receptors and in-
tracellular signaling mechanisms (Cha, 2000; Luthi Carter et al.,
2000), and environmental enrichment increases transcription of
some proteins, including neurotrophic factors, in the hippocam-
pus (Pham et al., 1999a,b; Young et al., 1999). Neurotrophins
contribute to the regulation of neuronal development, plasticity,
and survival, making them important in mediating the progres-
sion of neurodegenerative diseases. BDNF expression has specif-
ically been shown to be downregulated in human HD sufferers
(Ferrer et al., 2000a; Zuccato et al., 2001) and in R6/2 HD mice
(Luthi Carter et al., 2002), and wild-type huntingtin protein up-
regulates BDNF transcription (Zucatto et al., 2001).
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Expression of the HD mutation in transgenic mice also causes
downregulation of dopamine and cAMP-regulated phosphopro-
tein, 32 kDa (DARPP-32), a pivotal regulator of dopamine and
serotonin signaling (Bibb et al., 2000; van Dellen et al., 2000b),
and of dopamine receptors D1 and D2 (Cha et al., 1998).
DARPP-32 is enriched in prefrontal cortex and striatum (Ouimet
et al., 1984, 1992; Perez and Lewis, 1992), where it mediates do-
pamine and serotonin signaling (Svenningsson et al., 2002).
Here, we test whether environmental enrichment could be
ameliorating HD symptoms by rescuing protein deficits caused
by transcriptional dysregulation or disrupted protein trafficking.
In particular, we examine BDNF, NGF, and DARPP-32 protein
in the hippocampus, striatum, and the anteromedial cortex,
which projects densely to the striatum. Our results not only sug-
gest a molecular basis for the beneficial effects of enrichment but
also point to a possible mechanism of the disease process.
Materials and Methods
Animals. R6/1 mice transgenic for the promoter and exon 1 of the ex-
panded human huntingtin gene and littermate wild-type controls were
bred in-house from a colony that originated from crossing male R6/1
mice (Mangiarini et al., 1996) (The Jackson Laboratory, Bar Harbor,
ME) with female CBA mice. The R6/1 male offspring were crossed again
with CBA females for several generations (past F10) to attain an almost
pure CBA background. A single background strain is important to ensure
consistency in behavioral testing. Groups of four to six mice were housed
in large-sized rodent cages (dimensions, 44  28  12.5 cm) with ad
libitum access to food and water. Half of the mice (selected randomly)
were given environmental enrichment in the home cage from the age of
4 weeks, whereas the other half received only normal bedding. At 4 weeks
of age, tail tissue was taken from experimental animals for PCR genotyp-
ing, and a microchip (Labtrac, Uckfield, UK) was inserted subcutane-
ously for identification under general anesthesia induced with hypnorm
(fentanyl citrate; Janssen Pharmaceutica, Berse, Belgium) and hypnovel
(midazolam; Roche, Hertforshire, UK) in distilled water (1:1:2; 2.7 ml/
kg). Approximately half of the animals carried the HD transgene. Both
male and female mice were used in these experiments in equal numbers.
In previous studies, BDNF immunoreactivity had been indistinguishable
between the sexes (Conner et al., 1997). All animal work conformed to
United Kingdom regulations and was performed under a Home Office
project license.
Environmental enrichment. Enriched mice were exposed to nontoxic
objects placed in the home cage that were changed every 2 d (van Dellen
et al., 2000a). The objects consisted of small cardboard boxes, small open
wooden boxes, cylindrical cardboard tunnels 3 cm in diameter, and
folded sheets of paper10 10 cm.
Behavioral testing. A cohort of mice at 5 months of age consisting of 80
mice [15 wild-type non-enriched (WTNE), 24 HD non-enriched
(HDNE), 18 wild-type enriched (WTE), and 23 HD enriched (HDE)]
was tested for motor function.
A rotarod (Ugo Basile model 7650; Sandown Scientific, Hampton,
UK) was used as a measure of motor symptoms. For this test, mice were
placed on a 6 cm section of the central cylinder of the apparatus,
which was 3 cm in diameter and had 2 mm longitudinal ridges. The
cylinder rotated at an initial rate of 3.5 rpm and accelerated gradually
at 20 rpm/min to a maximum of 40 rpm. When a mouse could no
longer stay on the rod, it fell a few centimeters onto a sprung platform,
and the amount of time that the mouse remained on the accelerating
rod was recorded.
Tissue preparation. Tissue samples were obtained from mice aged 5
months (10 WTNE, 7 HDNE, 7 WTE, and 6 HDE). Mice were weighed
(N2B110; Ohaus, Pine Brook, NJ) then deeply anesthetized with pento-
barbitone (Euthetal; 200 mg/kg, i.p.; Rhone Merieux, Harlow, UK) and
decapitated. Brains were removed quickly and weighed (Precisa 125A;
Precisa, Milton Keynes, UK), and the striatum, anteromedial quarter of
the cortical sheet, and hippocampus were dissected on ice. Dissected
tissue samples were weighed and homogenized (homogenizer from Fi-
scher Scientific, Pittsburgh, PA) in 0.1 M PBS (10 v/w; Sigma, St Louis,
MO) containing protease inhibitor mixture (1:25 v/v; P8340; Sigma).
Protein concentration in homogenized samples was determined using
the Bradford method (Bio-Rad DC protein assay; Bio-Rad, Hercules,
CA), and samples were stored at80°C. Each sample was coded so that
experiments and analyses were performed blind to genotype and housing
conditions.
Immunoblotting. Equal amounts of protein from each sample were
boiled for 5 min in sample buffer containing 5% mercaptoethanol, 2%
SDS, and 10% glycerol (Sigma). Proteins were separated on 10% poly-
acrylamide gels by SDS-PAGE at 50 mA (Bio-Rad mini-protean system),
then transferred overnight at 30 V onto 0.45 m nitrocellulose (Bio-
Rad). To confirm that equal amounts of protein were transferred from
each sample, membranes were stained with 0.1% amido dye (Sigma) in
distilled water then digitally scanned and analyzed using Image software
(Scion, Fredrick, MD). The total amount of protein on the tested mem-
branes never varied 5% between lanes. After amido staining, mem-
branes were rinsed, then probed for BDNF, NGF, or DARPP-32 immu-
noreactivity using ECL (Amersham, Little Chalfont, UK) according to
the manufacturer’s instructions. Briefly, membranes were blocked for 1
hr in 5% powdered milk in PBS buffer containing 0.1% Triton detergent
(PBST; Sigma) at pH 7.4, followed by a 2 hr incubation in primary
antibodies to BDNF (Santa Cruz 546; Santa Cruz Biotechnology, Santa
Cruz, CA), NGF (Santa Cruz Biotechnology), or DARPP-32 (Chemicon,
Temecula, CA) diluted in PBST to final concentrations of 1:1000 BDNF,
1:1000 NGF, or 1:10,000 DARPP-32. After washing, a solution of second-
ary HRP-conjugated anti-rabbit antibody (Amersham) at a dilution of
1:1000 in PBST was applied to the membrane and incubated for 1 hr.
Bands were visualized with ECL developing solution (Amersham). For
each condition, more than one immunoblot was performed to ensure
reproducibility. One of the blots from each condition was also
stripped in buffer containing 0.2 M glycine (Sigma), pH 2.5, for 20 min
at 80°C, then reprobed for -tubulin (Covance Research Products,
Berkeley, CA) at a concentration of 1:5000 as an additional control of
equal protein loading.
Analysis. Averages (and SEM) were calculated for rotarod perfor-
mance, body weight, and brain weight for each experimental group. The
effects of the R6/1 genotype and enriched versus non-enriched housing
conditions were assessed by two-way ANOVA using SPSS software
(SPSS, Chicago, IL). The means of individual groups were compared
using post hoc two-tailed t tests for independent variables with equal
variance not assumed (SPSS).
Relative protein concentrations were quantified by comparing optical
densities of protein bands using Image software (Scion). The optical
density of each sample on the blot was normalized to the average optical
density of all WTNE samples, giving a value of protein level as a percent-
age of WTNE. Averages for each group and SEM were calculated. The
effects of the HD transgene and housing condition were analyzed using
two-way ANOVA, and the means of individual groups were again com-
pared using t tests (SPSS).
Results
Environmental enrichment ameliorates motor symptoms
of HD
In non-enriched R6/1 mice, the onset of motor symptoms occurs
at around 2 months of age, and by 5 months, all HDNE mice
exhibit motor deficits (Mangiarini et al., 1996; van Dellen et al.,
2000a). Environmental enrichment delays disease onset, and at 5
months, less than half of HDE mice exhibit motor symptoms
(van Dellen et al., 2000a).
Using the accelerating rotarod test as an indicator of motor
symptoms, we confirmed that prior environmental enrichment
improves motor performance at 5 months (Fig. 1) (two-way
ANOVA; F(1,76)  22.452; p  0.0001). HDNE mice performed
much worse than WTNE animals (t test; p 0.019), and enrich-
ment increases the time that HD animals spend on the rod com-
pared with WTNE animals (t test; p 0.029) and HDNE animals
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(t test; p 0.001). Thus, environmental enrichment completely
alleviates the HD-induced deficit in rotarod performance at this
age.
Body weight is significantly decreased by the HD transgene
(Fig. 2) (two-way ANOVA; F(1,27) 5.690; p 0.024). Environ-
mental enrichment partially ameliorates this HD-induced loss.
Post hoc t tests confirmed that HDNE animals weigh less than
WTNE mice (t test; p  0.045). Enriched animals carrying the
transgene are not significantly lighter than WTNE or WTE ani-
mals, indicating that enrichment prevents some of the weight loss
associated with HD.
The HD transgene also causes a decrease in brain weight (Fig.
2b) (two-way ANOVA; F(1,27) 42.118; p 0.001), and enrich-
ment increases brain weight (two-way ANOVA; F(1,27)  7.597;
p 0.010). Environmental enrichment slightly, but significantly,
increases brain weight in wild-type animals (t test; p  0.027).
However, the HD-induced decrease in brain weight of non-
enriched animals is not rescued. HDE animals have lower brain
weight than either WTNE (t test; p 0.013) or WTE (t test; p
0.001) animals. Enrichment does not significantly increase brain
weight in HD animals at this age, although there is a trend toward
heavier brains in HDE animals compared with HDNE animals
( p 0.083).
Environmental enrichment rescues specific striatal and
hippocampal BDNF deficits
ECL for BDNF (Fig. 3) labeled a single band at 14 kDa corre-
sponding to the dimer of mature BDNF. A doublet (or triplet)
averaging 42 kDa was also labeled in all three brain areas exam-
ined, which may correspond to a precursor form of the protein
prepro BDNF (ppBDNF). The Santa Cruz BDNF antibody used
here has been used previously to quantify BDNF protein levels in
human (Ferrer et al., 2000a,b; Dwivedi et al., 2003) and rodent
(Fawcett et al., 2000).
We found that BDNF is dramatically reduced in the striatum
of non-enriched symptomatic HD mice, as in human HD (Ferrer
et al., 2000a). Even as early as 5 months of age, BDNF protein
levels are 30% lower in the striatum of HDNE mice than in
WTNE animals (t test; p  0.021) (Fig. 3a). Encouragingly, en-
richment, which clearly reduces symptoms at this early stage in
the disease (Fig. 1) (van Dellen et al., 2000a), increases striatal
BDNF levels (two-way ANOVA; F(1,25)  16.055; p 0.001). In
the striatum of HDE mice, this increase more than compensates
for the reduction of BDNF seen in HDNE animals, so that no
deficit in protein level remains (Fig. 3a). Post hoc t tests reveal an
increase in BDNF with enrichment in HD mice when compared
with WTNE ( p 0.010) and HDNE ( p 0.001) animals. WTE
animals also have higher levels of BDNF than HDNE mice ( p
0.015).
BDNF is not manufactured in the striatum but is antero-
gradely transported to it, especially from the cerebral cortex (Al-
tar et al., 1997; Conner et al., 1997). In the anteromedial cortex of
R6/1 HD mice, there is no obvious effect of HD on BDNF expres-
sion, suggesting that the HD mutation perturbs transport of
BDNF from the cortex to striatum, and this effect is rectified by
enrichment (Fig. 3b).
In the hippocampus, there is also an HD-induced BDNF def-
icit in non-enriched mice (Fig. 3c) but no difference in BDNF
levels between HDE mice and WTE mice (t test; p  0.621) or
WTNE mice (trend toward decrease: t test; p 0.064). This sug-
gests that enrichment rescues the BDNF levels in hippocampus as
in the striatum. Interestingly, although it prevents the decrease of
BDNF levels associated with HD, environmental enrichment
causes a decrease in BDNF levels in WT mice. BDNF mRNA is
found in the hippocampus (Conner et al., 1997), indicating that
the deficit in this area may be attributable to transcriptional dys-
regulation or altered catabolism of the protein and not necessar-
ily disrupted protein trafficking, as we suggest for the striatum.
However, we cannot rule out the possibility that areas projecting
to the hippocampus (such as the entorhinal cortex) send BDNF
to this area and that HD disrupts transport.
NGF, another important neurotrophin, is not affected by the
HD transgene in the striatum, anterior cortex, or hippocampus
(Fig. 4), indicating that the deficit in BDNF and the ameliorating
effect of enrichment are specific to BDNF and that enrichment is
not acting via blanket upregulation of neurotrophins. In fact,
enrichment slightly decreases NGF levels in the striatum of wild-
type mice (Fig. 4a).
Environmental enrichment rescues a cortical
DARPP-32 deficit
DARPP-32, a pivotal regulator of dopamine signaling, is down-
regulated in the striatum of R6/2 HD mice (Bibb et al., 2000;
Luthi Carter et al., 2000), and reductions in DARPP-32 have been
shown by qualitative observation of immunostaining in R6/1
mice (Van Dellen et al., 2000b). Here, we quantitatively confirm
the DARPP-32 deficit in R6/1 symptomatic mice using Western
Figure 1. Environmental enrichment enhances rotarod performance in HD and wild-type
mice. At 5 months, environmental enrichment rescues an HD-induced deficit in performance on
the accelerating rotarod. Bars represent post hoc t tests: *p 0.05; **p 0.001.
Figure 2. HD causes a decrease in body and brain weight. a, The HD transgene causes a
dramatic decrease in body weight of R6/1 mice at 5 months of age, and enrichment compen-
sates for this loss. b, Brain weight is also reduced by the HD transgene, but enrichment increases
brain weight in wild-type animals at 5 months. The enrichment-induced increase is not enough
to compensate for the weight loss in HD. Bars represent post hoc t tests: *p 0.05; **p
0.001.
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blotting and ECL and explore the effects of environmental en-
richment on DARPP-32 expression.
In the striatum at 5 months, DARPP-32 levels are significantly
reduced, by 25%, in the striatum of HDNE mice (Fig. 5a)
(t test; p 0.001). However, this deficit is not rescued by enrich-
ment: striatal DARPP-32 levels are decreased in HDE mice when
compared with WTNE animals (t test; p 0.004) and WTE ani-
mals (t test; p 0.026). At the same age in the anterior cortex, the
HD transgene also causes a decrease in DARPP-32 protein levels
of 25% in non-enriched mice (Fig. 5b) (t test; p  0.031).
However in this area, environmental enrichment rescues the HD-
induced deficit. DARPP-32 levels in the anterior cortex of HDE
mice do not differ from WTNE ( p 0.433) or WTE ( p 0.290)
mice. The increase in DARPP-32 with enrichment in HD mice,
compared with HDNE mice, almost
reached significance ( p 0.056).
DARPP-32 mRNA is produced in both
the striatum and cortex (Perez and Lewis,
1992), and striatal mRNA levels are known
to be decreased by HD in another mouse
model (Bibb et al., 2000; Luthi Carter et al.,
2000). Thus, the decreases in the cortex
and striatum of DARPP-32 protein ob-
served here are probably attributable to
transcriptional downregulation that is rec-
tified by enrichment in the cortex.
Discussion
We have demonstrated that environmen-
tal enrichment ameliorates motor symp-
toms and rescues specific protein deficits
in R6/1 mice. This indicates a possible mo-
lecular basis for the observed behavioral
benefits of increased environmental stim-
ulation, in both mice and human HD suf-
ferers (van Dellen et al., 2000a; Sullivan et
al., 2001; Hockly et al., 2002), and it points
to a possible pathogenic mechanism of the
disease process itself.
We show that environmental enrich-
ment ameliorates motor symptoms at 5
months measured using the accelerating
rotarod test, as would be expected from
previous studies showing alleviation of
symptoms at this age (van Dellen et al.,
2000a). Enrichment also rescues the HD-
induced decrease in body weight at 5
months. Although we find that enrich-
ment increases total brain weight in wild-
type animals as has been seen previously
(Bennett et al., 1964; Rosenzweig and Ben-
nett, 1996), the increase does not compen-
sate for the HD-induced reduction. How-
ever, at the same age, enrichment of HD
mice does rescue the specific decrease in
volume of the area of forebrain surround-
ing the neostriatum (van Dellen et al.,
2000a).
We investigate further the underlying
molecular mechanisms of enrichment by
examining protein levels in the striatum,
anterior cortex, and hippocampus. Envi-
ronmental enrichment rescues cortical,
but not striatal, DARPP-32 levels in R6/1
HD mice at 5 months. Because DARPP-32 mRNA is present in
both the cortex and striatum, we propose that the reduction of
this protein with HD is attributable to transcriptional downregu-
lation, as has been reported previously (Bibb et al., 2000; Luthi
Carter et al., 2002). In the case of cortical DARPP-32, enrichment
may then act by rescuing transcriptional abnormalities.
Downregulation of DARPP-32 (Bibb et al., 2000; van Dellen et
al., 2000b) and of D1 and D2 dopamine receptors (Cha, 2000)
disrupts dopamine signaling in the striatum and may contribute
to neuronal dysfunction. The serotonergic and dopaminergic
neurotransmitter systems, which signal through DARPP-32,
contribute to cognition, emotion, mood, and reward. Deficits in
these pathways caused by HD could contribute to psychiatric and
Figure 3. An HD-induced striatal BDNF deficit is rescued by environmental enrichment. ECL using an anti-BDNF antibody on
tissue from the striatum, anteromedial cortex, and hippocampus shows the mature form of BDNF protein at 14 kDa and a doublet
(or triplet) at 42 kDa, which corresponds to the prepro form of the protein (ppBDNF). a, Histograms of average BDNF levels
(expressed as a percentage of WTNE levels SEM), show that HD causes a decrease of 30% in BDNF protein in the striatum at 5
months that is rescued by enrichment. Environmental enrichment rescues the deficit by increasing BDNF levels40% over WTNE
levels (two-way ANOVA; F(1,25) 6.387; p 0.05). b, In the anteromedial cortex, there is no effect of HD or enrichment on BDNF
levels, suggesting that enrichment may compensate for a deficit in corticostriatal anterograde transport of BDNF. c, In the
hippocampus, there is an HD-induced BDNF deficit in non-enriched animals that is rescued by environmental enrichment. In
wild-type animals, enrichment actually decreases the level of BDNF in the hippocampus. After probing for BDNF, blots were
stripped and reprobed for neuronal-tubulin as a control of equal protein loading. Control bands are shown below BDNF bands
in all conditions. Bars represent post hoc t tests: *p 0.05.
Spires et al. • Enrichment Rescues Protein Deficits in Huntington’s Disease J. Neurosci., March 3, 2004 • 24(9):2270 –2276 • 2273
cognitive symptoms of the disease. In the
DARPP-32 knock-out mouse, both dopa-
mine and serotonin signaling are dis-
rupted (Fienberg and Greengard, 2000;
Svenningsson et al., 2002), and reversal
learning is impaired (Heyser et al., 2000).
Hence, the rescue of cortical DARPP-32
deficits in R6/1 HD mice may contribute
to observed behavioral benefits of enrich-
ment by ameliorating aspects of neuronal
dysfunction caused by disruption of dopa-
mine and serotonin signaling.
Our most compelling finding is that
environmental enrichment prevents stria-
tal and hippocampal deficits in BDNF at a
stage of the disease when HDE mice show
far less severe motor symptoms than their
HDNE littermates, as demonstrated in
previous studies (van Dellen et al., 2000a)
and by the rotarod experiment reported
here (Fig. 1). In the striatum, enrichment
causes an upregulation of BDNF that
could explain the enhanced performance
of both WTE and HDE mice on the rotarod. Neurotrophic fac-
tors facilitate neuronal development, plasticity, and survival, so
their reduction could potentially be important in the pathological
progression of neurodegenerative diseases. BDNF has specifically
been shown to induce neurogenesis in the striatum, with new
neurons expressing markers specific for medium spiny neurons,
including DARPP-32 (Benraiss et al., 2001).
The upregulation of BDNF in the striatum with enrichment is
specific to this neurotrophin because NGF levels are not raised by
enrichment in this area. On the contrary, NGF levels in striatum
are decreased by enrichment in wild-type mice. Differential re-
sponse of neurotrophins to striatal distress has been observed
previously (Canals et al., 1998).
We suggest that the decrease in BDNF protein in R6/1 striatum
could be attributable to a disruption of corticostriatal anterograde
transport of BDNF because levels of this neurotrophin are unaf-
fected by the transgene in the cortex, which transports it to the stri-
atum. However, the unchanged cortical levels of BDNF do not nec-
essarily mean that the transgene is not affecting transcription.
Transcription could be decreased by the transgene, but impaired
anterograde trafficking could result in BDNF staying in the cortex
instead of being shipped to the striatum. If the decrease of BDNF in
the striatum is indeed attributable to disrupted corticostriatal trans-
port, we would not expect to see an effect on NGF acting through the
same mechanism, because NGF is not transported in the same man-
ner. NGF is typically transported retrogradely, as in the case of basal
forebrain cholinergic neurons (for review, see Sofroniew et al.,
2001). Furthermore, it is endogenously expressed in the striatum by
a subpopulation of interneurons (Bizon et al., 1999).
Rescuing BDNF levels in the striatum might promote cell sur-
vival and upregulate genes that are normally transcriptionally
disrupted in HD, thus protecting against neuronal dysfunction.
Indeed, BDNF specifically promotes survival of striatal projec-
tion neurons in an excitotoxic model of striatal neurodegenera-
tion (Alberch et al., 2002). Furthermore, excitotoxic lesioning of
the striatum in normal mice induces upregulation of BDNF in the
cortical neurons responsible for supplying BDNF to the striatum
via anterograde transport (Canals et al., 2001).
Figure 4. HD does not affect NGF levels. NGF protein levels are not affected by HD at 5 months in the striatum ( a), anteromedial cortex ( b), or hippocampus ( c). Enrichment slightly decreases the
level of NGF in the striatum but does not affect levels in the other areas (t test; * p 0.05).
Figure 5. Enrichment corrects cortical DARPP-32 deficits. a, DARPP-32 levels are reduced, by25%, in the striatum of HD mice
at 5 months; however, this deficit is not rescued by enrichment at this age. In the anteromedial cortex of non-enriched mice ( b),
DARPP-32 levels are significantly lower in HD as opposed to wild-type (WT) mice. Environmental enrichment entirely rescues the
HD-induced DARPP-32 deficit in this area. Bars represent post hoc t tests: *p 0.05; **p 0.01.
2274 • J. Neurosci., March 3, 2004 • 24(9):2270 –2276 Spires et al. • Enrichment Rescues Protein Deficits in Huntington’s Disease
Normal huntingtin protein promotes BDNF transcription
(Zuccato et al., 2001) and is involved in vesicular trafficking (Di-
Figlia et al., 1995). If environmental enrichment does indeed mit-
igate a deficit in corticostriatal anterograde transport of BDNF
resulting from aberrant huntingtin, it might then partially com-
pensate for this basic genetic failure. Our results lead us, then, to
speculate that defects in corticostriatal transport might be a basic
early pathogenic mechanism in HD.
We observe that environmental enrichment rescues an HD-
induced BDNF deficit in the hippocampus as well as the striatum,
but unlike in the striatum, enrichment causes a decrease in hip-
pocampal BDNF level of wild-type animals. Although enrich-
ment is generally seen to upregulate neurotrophins (Pham et al.,
1999b; Young et al., 1999), inhibitory effects of enrichment on
protein expression have also been observed. For example, in rats
with focal strokes induced by cerebral ischemia, environmental
enrichment prevents the increase in BDNF levels in hippocampus
and cortex seen in non-enriched animals (Zhao et al., 2001).
Functionally, the decrease in BDNF levels in the hippocampus
may lead to decreased excitation, which would prevent excitotox-
icity, because BDNF enhances spontaneous activity (Lessmann et
al., 1994) and inhibits GABAergic transmission in this brain area
(Tanaka et al., 1997).
The experiments presented here do not address which aspects
of enrichment (cognitive stimulation, exercise, or feeding pat-
terns) contribute to its beneficial effects. Cognitive stimulation in
humans is important in preventing some aspects of neurodegen-
erative disease. Participating in cognitively stimulating activities
has been associated with a reduced risk of Alzheimer’s disease
(Wilson et al., 2002), and lack of education increases the risk of
dementia in Parkinson’s disease (Glatt et al., 1996). Recent stud-
ies showed that exercise can increase BDNF levels in rats (Russo
Neustadt et al., 2001; Berchtold et al., 2002). Enriched animals
also eat less than non-enriched animals (Fiala et al., 1977), and a
recent study has shown that dietary restriction can rescue BDNF
levels and enhance motor performance in an HD model (Duan et
al., 2003).
The involvement of corticostriatal BDNF transport in HD
pathology and the rescue of DARPP-32 levels in the cortex high-
light the importance of the cortex, and specifically the anterior
cortex in this disease. In R6 transgenic mouse models, neurode-
generation, in the form of dark degenerating neurons, is most
pronounced in the dorsal striatum and anterior cingulate cortex
(Davies et al., 1999; Turmaine et al., 2000). The anteromedial area
of cortex examined in our experiments includes anterior cingu-
late cortex, which has dense projections to the striatal medium
spiny neurons that selectively degenerate in HD. Anterior cingu-
late cortex is involved in emotional responses and in sensory,
motor, and cognitive processing (Vogt et al., 1992). Positron
emission tomographic studies in patients with HD have revealed
impairment of activity in the anterior cingulate cortex as well as
the striatum (Mayberg et al., 1992). In R6/1 mice, transplantation
of wild-type donor cortex to replace diseased anterior cingulate
cortex delays the onset of a specific motor symptom of HD (van
Dellen et al., 2001).
Taken together, these results imply that enrichment might act
by reducing specific striatal, cortical, and hippocampal protein
deficits. Specifically, the increase in neuronal activity in somato-
sensory, motor, and frontal cortices associated with enrichment
may compensate for corticostriatal BDNF trafficking deficits. In-
deed, BDNF transported anterogradely along axons has been
shown to transfer to postsynaptic cells in an activity-dependent
manner (Kohara et al., 2001). Reductions in BDNF expression in
the hippocampus and DARPP-32 in the anterior cortex and stri-
atum may also be counteracted by increased activity causing tran-
scriptional upregulation (as seen in enriched rats) (Pham et al.,
1999b). Our results show that environmental enrichment
strongly influences the cortex and support the idea that early
changes in the cortex contribute to HD pathogenesis. Finally, we
suggest that BDNF might be a promising target for new therapeu-
tic approaches to this devastating disease.
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